344 related articles for article (PubMed ID: 26867931)
21. Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives.
Ghasemian A; Al-Marzoqi AH; Al-Abodi HR; Alghanimi YK; Kadhum SA; Shokouhi Mostafavi SK; Fattahi A
J Cell Physiol; 2019 Nov; 234(11):19271-19279. PubMed ID: 30993718
[TBL] [Abstract][Full Text] [Related]
22. PEGylated
Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
[TBL] [Abstract][Full Text] [Related]
23. Cloning, expression and characterisation of Erwinia carotovora L-asparaginase.
Kotzia GA; Labrou NE
J Biotechnol; 2005 Oct; 119(4):309-23. PubMed ID: 15951039
[TBL] [Abstract][Full Text] [Related]
24. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences.
Burke MJ; Zalewska-Szewczyk B
Future Oncol; 2022 Mar; 18(10):1285-1299. PubMed ID: 35107320
[TBL] [Abstract][Full Text] [Related]
25. L-Asparaginase Isolated from Phaseolus vulgaris Seeds Exhibited Potent Anti-Acute Lymphoblastic Leukemia Effects In-Vitro and Low Immunogenic Properties In-Vivo.
Mohamed SA; Elshal MF; Kumosani TA; Aldahlawi AM; Basbrain TA; Alshehri FA; Choudhry H
Int J Environ Res Public Health; 2016 Oct; 13(10):. PubMed ID: 27754445
[No Abstract] [Full Text] [Related]
26. Identification of functional regions in the Rhodospirillum rubrum L-asparaginase by site-directed mutagenesis.
Pokrovskaya MV; Aleksandrova SS; Pokrovsky VS; Veselovsky AV; Grishin DV; Abakumova OY; Podobed OV; Mishin AA; Zhdanov DD; Sokolov NN
Mol Biotechnol; 2015 Mar; 57(3):251-64. PubMed ID: 25370827
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
Avramis VI; Panosyan EH
Clin Pharmacokinet; 2005; 44(4):367-93. PubMed ID: 15828851
[TBL] [Abstract][Full Text] [Related]
28. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.
Castaman G; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):57-60. PubMed ID: 8039761
[TBL] [Abstract][Full Text] [Related]
29. [Mechanisms of development of side effects and drug resistance to asparaginase and ways to overcome them].
Alexandrova SS; Gladilina YA; Pokrovskaya MV; Sokolov NN; Zhdanov DD
Biomed Khim; 2022 Apr; 68(2):104-116. PubMed ID: 35485484
[TBL] [Abstract][Full Text] [Related]
30. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
[TBL] [Abstract][Full Text] [Related]
31. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia.
Zalewska-Szewczyk B; Andrzejewski W; Bodalski J
Pediatr Blood Cancer; 2004 Oct; 43(5):600-2. PubMed ID: 15382279
[TBL] [Abstract][Full Text] [Related]
32. Improvement in the therapeutic, immunological, and clearance properties of Escherichia coli and Erwinia carotovora L-asparaginases by attachment of poly-DL-alanyl peptides.
Uren JR; Ragin RC
Cancer Res; 1979 Jun; 39(6 Pt 1):1927-33. PubMed ID: 376113
[TBL] [Abstract][Full Text] [Related]
33. Beta-aspartylpeptides as substrates of L-asparaginases from Escherichia coli and Erwinia chrysanthemi.
Kelo E; Noronkoski T; Stoineva IB; Petkov DD; Mononen I
FEBS Lett; 2002 Sep; 528(1-3):130-2. PubMed ID: 12297292
[TBL] [Abstract][Full Text] [Related]
34. [Purification and properties of recombinant Erwinia carotovora L-asparaginase expressed in E.coli cells].
Borisova AA; El'darov MA; Zhgun AA; Aleksandrova SS; Omel'ianiuk NM; Sokov BN; Berezov TT; Sokolov NN
Biomed Khim; 2003; 49(5):502-7. PubMed ID: 16119104
[TBL] [Abstract][Full Text] [Related]
35. Impact of clinical and subclinical hypersensitivity to asparaginase in acute lymphoblastic leukemia.
Asselin BL; Fisher V
Clin J Oncol Nurs; 2014 Dec; 18(6):E107-12. PubMed ID: 25427712
[TBL] [Abstract][Full Text] [Related]
36. Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.
Yen HJ; Chang WH; Liu HC; Yeh TC; Hung GY; Wu KH; Peng CT; Chang YH; Chang TK; Hsiao CC; Sheen JM; Chao YH; Chang TT; Chiou SS; Lin PC; Wang SC; Lin MT; Ho WL; Chen YC; Liang DC
Pediatr Blood Cancer; 2016 Apr; 63(4):665-70. PubMed ID: 26703788
[TBL] [Abstract][Full Text] [Related]
37. Immunological relationships of bacterial L-asparaginases.
Bascomb S; Bettelheim KA
J Gen Microbiol; 1976 Jan; 92(1):175-82. PubMed ID: 54404
[TBL] [Abstract][Full Text] [Related]
38. Monitoring of anti-L-asparaginase antibody and L-asparaginase activity levels in a pediatric patient with acute lymphoblastic leukemia and hypersensitivity to native Escherichia coli L-asparaginase during desensitization courses.
Kawahara Y; Morimoto A; Hayase T; Kashii Y; Fukuda T; Momoi MY
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e91-3. PubMed ID: 23689289
[TBL] [Abstract][Full Text] [Related]
39. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
Pieters R; Hunger SP; Boos J; Rizzari C; Silverman L; Baruchel A; Goekbuget N; Schrappe M; Pui CH
Cancer; 2011 Jan; 117(2):238-49. PubMed ID: 20824725
[TBL] [Abstract][Full Text] [Related]
40. [Antitumor activity of L-asparaginase from Erwinia carotovora from against different leukemic and solid tumours cell lines].
Abakumova OIu; Podobed OV; Karalkin PA; Kondakova LI; Sokolov NN
Biomed Khim; 2013; 59(5):498-513. PubMed ID: 24479339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
